Oral News and Research

RSS

Scientists propose improved method of screening salmonella vaccines in small animal studies

An innovative vaccine technology makes use of reengineered salmonella to deliver protective immunity. If such recombinant attenuated salmonella vaccines or RASVs can be perfected, they hold the promise of safe, lost-cost, orally administered defenses against viral, bacterial, fungal and parasitic infections.

19 Feb 2014

Viamet announces positive interim results from VT-1161 Phase 2 study in patients with AVVC

Viamet Pharmaceuticals Inc. today reported positive interim results from an ongoing Phase 2 study of VT-1161, the Company's novel oral antifungal compound, in patients with moderate to severe acute vulvovaginal candidiasis (AVVC). This study is intended as a precursor to a Phase 2b study in patients with recurrent vulvovaginal candidiasis (RVVC).

18 Feb 2014

BMG Pharma signs agreement with Samyang Biopharmaceutical to market GelX in South Korea

BMG Pharma S.r.l. today is pleased to announce that it has signed an exclusive distribution agreement with Samyang Biopharmaceutical Corporation granting them the rights to promote, sell and market its novel mucositis management product GelX in the territory of South Korea.

17 Feb 2014

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, today announced that it plans to discontinue the sale of NAMENDA (memantine HCl) 5 mg and 10 mg tablets effective August 15, 2014.

16 Feb 2014

TPI announces financial results for second quarter fiscal year 2014

Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the second quarter fiscal year 2014.

14 Feb 2014

FDA approves Biologics’ IMBRUVICA as oral agent for treatment of patients with CLL

Biologics, a limited distribution network partner for IMBRUVICA™ (ibrutinib), is pleased to announce the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) capsules as a single, oral agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

14 Feb 2014

Hospi receives FDA clearance for Macy Catheter

Hospi Corporation, a privately-held medical device company focused on nurse invented products that optimize patient care, today announced receipt of 510(k) clearance from the U.S. Food and Drug Administration for its first product, the Macy Catheter. The Macy Catheter is the only device designed and approved solely for ongoing rectal delivery of medications and liquids.

13 Feb 2014

Manchester researchers become first in world to assess all genetic links with fungal lung infection CPA

A grandfather-of-three from Tameside is helping University of Manchester researchers become the first in the world to assess all the genetic links with Chronic Pulmonary Aspergillosis (CPA) - a debilitating fungal lung infection that claims the lives of thousands of people in the UK and millions more worldwide.

From The University of Manchester 12 Feb 2014

Obama administration to delay requirement for mid-sized employers to provide health insurance to workers

Officials announced Monday that the government will not enforce the mandate for businesses with 50 to 99 workers until 2016. In addition, larger employers will also be allowed to cover just 70 percent of workers in 2015, instead of the 90 percent originally required.

12 Feb 2014

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled "Compositions Comprising TNF-specific Antibodies for Oral Delivery."

12 Feb 2014

Researchers demonstrate new approach to treating muscular dystrophy

Researchers at Washington University School of Medicine in St. Louis have demonstrated a new approach to treating muscular dystrophy. Mice with a form of this muscle-weakening disease showed improved strength and heart function when treated with nanoparticles loaded with rapamycin, an immunosuppressive drug recently found to improve recycling of cellular waste.

12 Feb 2014

IMF announces approval of POMALYST medication in Canada for patients with myeloma

The International Myeloma Foundation - improving the quality of life of myeloma patients while working toward prevention and a cure - said POMALYST (pomalidomide) approval by Health Canada provides patients the most up-to-date oral therapy available for patients who have exhausted all other treatments.

11 Feb 2014

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.

11 Feb 2014

Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

Ario Pharma Ltd, the Cambridge biopharmaceutical company developing innovative new approaches to treat respiratory disease, announced today that it has commenced a Phase IIa study of its TRPV1 antagonist, XEN-0501, for the treatment and prevention of cough in patients with chronic obstructive pulmonary disease (COPD). Persistent cough in COPD and other respiratory conditions present as a huge unmet medical need, with novel therapies urgently needed to improve the quality of life of patients.

11 Feb 2014

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

Alba Therapeutics Corporation announced today the positive results of their Phase IIb trial evaluating its investigational product, larazotide acetate, a first-in-class tight junction regulator, intended for the treatment of patients with celiac disease (CeD).

11 Feb 2014

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Ligand Pharmaceuticals Incorporated today reported financial results for the three and 12 months ended December 31, 2013, and provided an operating forecast and program updates.

11 Feb 2014

Neutra acquires cutting-edge developer of smoke-free nutraceutical delivery systems

Neutra Corp. (OTCBB: NTRR), a fast-growing provider of all-natural wellness solutions, announced today that it acquired Diamond Anvil Designs (DA), a cutting-edge developer of smoke-free nutraceutical delivery systems.

11 Feb 2014

State highlights: Wis. Bill would limit worker's comp medical costs; Democratic AG in N.C. to appeal abortion ultrasound ruling; Conn. Medicaid primary care docs double since 2011

Wisconsin would put tighter caps on how much doctors and physical therapists could be paid to treat injured patients covered by worker's compensation insurance, under a bill before lawmakers.

11 Feb 2014

Researchers promote scientific and health prevention culture among national population

The Mexican enterprise "Science that breathes" is supported by the National Institutes of Respiratory Diseases and Carcinology among others.

11 Feb 2014

Gilead submits NDA to FDA for fixed-dose combination of ledipasvir and sofosbuvir for hepatitis C infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults.

11 Feb 2014

Oral News and Research

Scientists propose improved method of screening salmonella vaccines in small animal studies

Viamet announces positive interim results from VT-1161 Phase 2 study in patients with AVVC

BMG Pharma signs agreement with Samyang Biopharmaceutical to market GelX in South Korea

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

TPI announces financial results for second quarter fiscal year 2014

FDA approves Biologics’ IMBRUVICA as oral agent for treatment of patients with CLL

Hospi receives FDA clearance for Macy Catheter

Manchester researchers become first in world to assess all genetic links with fungal lung infection CPA

Obama administration to delay requirement for mid-sized employers to provide health insurance to workers

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Researchers demonstrate new approach to treating muscular dystrophy

IMF announces approval of POMALYST medication in Canada for patients with myeloma

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Neutra acquires cutting-edge developer of smoke-free nutraceutical delivery systems

State highlights: Wis. Bill would limit worker's comp medical costs; Democratic AG in N.C. to appeal abortion ultrasound ruling; Conn. Medicaid primary care docs double since 2011

Researchers promote scientific and health prevention culture among national population

Gilead submits NDA to FDA for fixed-dose combination of ledipasvir and sofosbuvir for hepatitis C infection

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News